Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications

Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications

Clinical trials for MET inhibitors have demonstrated limited success for their use in colon cancer (CC). However, clinical efficacy may be obscured by a lack of standardisation in MET assessment for patient stratification. In this study, we aimed to determine the molecular context in which MET is de...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Stephanie G. Craig, Svenja Mende, Matthew P. Humphries, Victoria Bingham, Amélie Viratham Pulsawatdi, Maurice B. Loughrey, Helen G. Coleman, Stephen McQuaid, Richard H. Wilson, Sandra Van Schaeybroeck, Jacqueline A. James, Manuel Salto‐Tellez
Format: article
Langue:EN
Publié: Wiley 2021
Sujets:
c‐MET IHC protein
colon cancer
MET amplification
MET R970C mutation
MET RNA‐ISH
MET T992I mutation
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/0b8be54a07784f57bd958f3c8b5f5b03
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/0b8be54a07784f57bd958f3c8b5f5b03

Documents similaires